Seth Karol, MD - St. Jude Children's ...

Dr. Seth E. Karol, MD

Claim this profile

St. Jude Children's Research Hospital

Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
10 reported clinical trials
17 drugs studied

Area of expertise

1T-Lymphoblastic Leukemia/Lymphoma
Seth E. Karol, MD has run 9 trials for T-Lymphoblastic Leukemia/Lymphoma. Some of their research focus areas include:
BCR-ABL1 positive
FLT3 negative
BCR-ABL1 T315I positive
2Acute Lymphoblastic Leukemia
Seth E. Karol, MD has run 7 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:
BCR-ABL1 positive
BCR-ABL1 T315I positive
Trisomy 21 positive

Affiliated Hospitals

Image of trial facility.
St Jude Children's Research Hospital
Image of trial facility.
United States, Tennessee St. Jude Children's Research Hospital

Clinical Trials Seth E. Karol, MD is currently running

Image of trial facility.

Dasatinib or Venetoclax

for T-Cell Leukemia

This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or mixed phenotype acute leukemia. Primary Objective * To evaluate if the end of induction MRD-negative rate is higher in patients with T-ALL treated with dasatinib compared to similar patients treated with 4-drug induction on AALL1231. * To evaluate if the end of induction MRD-negative rate is higher in patients with ETP or near-ETP ALL treated with venetoclax compared to similar patients treated with 4-drug induction on AALL1231. Secondary Objectives * To assess the event free and overall survival of patients treated with this therapy. * To compare grade 4 toxicities, event-free survival (EFS) and overall survival (OS) of patients treated with this therapy in induction and reinduction to toxicities of similar patients treated on TOT17.
Recruiting1 award Phase 22 criteria
Image of trial facility.

Combination Therapy

for Acute Lymphoblastic Leukemia

The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Leukemia (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies. * To develop a central database of genomic and clinical findings. Secondary Objectives * To assess event free and overall survival data of patients enrolled on this study.
Recruiting3 awards Phase 4

More about Seth E. Karol, MD

Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Seth E. Karol, MD has experience with
  • Venetoclax
  • Cytarabine
  • Methotrexate
  • Intensive Antihypertensive Therapy
  • Conventional Antihypertensive Therapy
  • Dexamethasone

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Seth E. Karol, MD specialize in?
Seth E. Karol, MD focuses on T-Lymphoblastic Leukemia/Lymphoma and Acute Lymphoblastic Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved BCR-ABL1 positive patients, or patients who are FLT3 negative.
Is Seth E. Karol, MD currently recruiting for clinical trials?
Yes, Seth E. Karol, MD is currently recruiting for 6 clinical trials in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Seth E. Karol, MD has studied deeply?
Yes, Seth E. Karol, MD has studied treatments such as Venetoclax, Cytarabine, Methotrexate.
What is the best way to schedule an appointment with Seth E. Karol, MD?
Apply for one of the trials that Seth E. Karol, MD is conducting.
What is the office address of Seth E. Karol, MD?
The office of Seth E. Karol, MD is located at: St. Jude Children's Research Hospital, Memphis, Tennessee 38105 United States. This is the address for their practice at the St. Jude Children's Research Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.